Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 6/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927006 | 0.85 | HTR7 (0.63) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL6521520 | 0.83 | MEN1 (0.58) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL18795847 | 0.81 | HTR7 (0.57) | HTR7HTR1ADRD3DRD2HTR2A | |
| SCHEMBL19957707 | 0.81 | TDP1 (0.70) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL141699 | 0.78 | MAOB (0.61) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL28058027 | 0.77 | HTR5A (0.59) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL22640170 | 0.77 | HTR7 (0.73) | HTR7HTR1ADRD3DRD2 | |
| SCHEMBL7246965 | 0.77 | HTR5A (0.79) | TDP1HTR5AHRH3HTR7HTR1A | |
| SCHEMBL1925581 | 0.76 | HTR7 (0.61) | HRH3HTR7HTR1ADRD3DRD2 | |
| SCHEMBL15830569 | 0.76 | PRMT5 (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348577-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LLC (US) | 2022-11-03 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-10155761-B2 | CXCR4 receptor antagonists | PROXIMAGEN, LLC (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2927224-B1 | Receptor antagonists | PROXIMAGEN LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2927224-A1 | Receptor antagonists | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | TDP1 4573/4885HTR5A 605/4885HRH3 288/4885 |
| US-20220348577-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | TDP1 4573/4885HTR5A 605/4885HRH3 288/4885 |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | CXCR4, ACKR3, CXCR1 | TDP1 4711/4885HTR5A 601/4885HRH3 260/4885 |
| US-10155761-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | TDP1 4573/4885HTR5A 605/4885HRH3 288/4885 |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | TDP1 4573/4885HTR5A 605/4885HRH3 288/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | TDP1 4573/4885HTR5A 605/4885HRH3 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.